ERBB2 and breast carcinoma: This straightforward, cost-effective modification to the premedication protocol may improve tolerability in HER2-positive breast cancer and other antibody-based therapies.<h4>Trial registration</h4>UMIN000045181 (registered on August 18, 2021).